Evidence map›Paper›PMID 34493241›Full record

ArticleBMC cancer2021

CML derived exosomes promote tumor favorable functional performance in T cells.

Nazli Jafarzadeh, Mohammad Ali Gholampour, Mohammad-Reza Alivand, Saeideh Kavousi, Laleh Arzi, Fariba Rad, Majid Sadeghizadeh, Majid Pornour

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Application of exosomes in tumor immunity: recent progresses.Frontiers in cell and developmental biology · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?International journal of molecular sciences · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Nazli JafarzadehDepartment of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Mohammad Ali GholampourDepartment of Hematology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran.
Mohammad-Reza AlivandDepartment of Medical Genetics, Faculty of Medicine, Tabriz University of Medical sciences, Tabriz, Iran.
Saeideh KavousiDepartment of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Laleh ArziDepartment of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran.
Fariba RadCellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Majid SadeghizadehDepartment of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Sadeghma@modares.ac.ir.ORCID https://orcid.org/0000-0002-2497-3152
Majid PornourDepartment of Photo Healing and Regeneration, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran. ma.pornour@gmail.com.ORCID https://orcid.org/0000-0003-0500-1822
Tarbiat Modares University · IRAcademic Center for Education, Culture and Research · IRIslamic Azad University, Shahr-e-Qods Branch · IRTabriz University of Medical Sciences · IRYasuj University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeukemic cells facilitate the creation of the tumor-favorable microenvironment in the bone marrow niche using their secreted factors. There are not comprehensive details about immunosuppressive properties of chronic myelogenous leukemia-derived exosomes in the bone marrow stromal and immune compartment. We explained here that K562-derived exosomes could affect the gene expression, cytokine secretion, nitric oxide (NO) production, and redox potential of human primary cord blood-derived T cells (CB T cells).

methodsHuman primary cord blood-derived T cells were treated with K562-derived exosomes. We evaluated the expression variation of some critical genes activated in suppressor T cells. The alterations of some inflammatory and anti-inflammatory cytokines levels were assessed using ELISA assay and real-time PCR. Finally, NO production and intracellular ROS level in CB T cells were evaluated using Greiss assay and flow cytometry, respectively.

resultsOur results showed the over-expression of the genes involved in inhibitory T cells, including NQO1, PD1, and FoxP3. In contrast, genes involved in T cell activation such as CD3d and NFATc3 have been reduced significantly. Also, the expression of interleukin 10 (IL-10) and interleukin 6 (IL-6) mRNAs were significantly up-regulated in these cells upon exosome treatment. In addition, secretion of the interleukin 10, interleukin 6, and interleukin 17 (IL-17) proteins increased in T cells exposed to K562-derived exosomes. Finally, K562-derived exosomes induce significant changes in the NO production and intracellular ROS levels in CB T cells.

conclusionsThese results demonstrate that K562-derived exosomes stimulate the immunosuppressive properties in CB-derived T cells by inducing anti-inflammatory cytokines such as IL-10, reducting ROS levels, and arising of NO synthesis in these cells. Moreover, considering the elevation of FOXP3, IL-6, and IL-17 levels in these cells, exosomes secreted by CML cells may induce the fates of T cells toward tumor favorable T cells instead of conventional activated T cells.

Indexed as

Cell ProliferationCytokinesExosomesFetal BloodHumansK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTumor MicroenvironmentCytokinesChronic myelogenous leukemia (CML)-derivedExosomesHuman primary cord blood T cellImmunosuppressionTumor microenvironment

Identifiers

PMID34493241
PMCPMC8424959
OpenAlexW3196406220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.